Exatecan mesylate is a water soluble camptothecin (CPT) analog that exhibits a stronger topoisomerase-I inhibitory and antitumor activities and is highly effective against P-glycoprotein (P-gp) mediated multi-drug resistant cells. Several of the exatecan derivative based antibody-drug and peptide-drug conjugate payloads display high therapeutic indices universally across solid tumors.
Water soluble camptothecin (CPT) analog that exhibits a stronger topoisomerase-I inhibitory and antitumor activities
International journal of cancer, 72(4), 680-686 (1997-08-07)
We previously reported that DX-8951f, a novel water-soluble camptothecin analog, significantly inhibits the growth of various human and murine tumors in vitro and in vivo. The antitumor effects and topoisomerase I inhibitory activity of DX-8951f are stronger than those of
Molecular medicine reports, 19(1), 477-489 (2018-11-16)
Unresectable advanced pancreatic cancer (APC) is a highly lethal malignancy. Although numerous chemotherapeutic regimens are available, evidence regarding the survival extension, the life quality improvement, the associated risks and occurrence rates of adverse effects, is required. The effects of 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(27), 4441-4447 (2006-09-20)
Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic cancer. A multicenter, randomized, phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted. Eligibility
